ALREX Drug Patent Profile
✉ Email this page to a colleague
When do Alrex patents expire, and what generic alternatives are available?
Alrex is a drug marketed by Bausch And Lomb and is included in one NDA.
The generic ingredient in ALREX is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alrex
A generic version of ALREX was approved as loteprednol etabonate by SENTISS on April 17th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALREX?
- What are the global sales for ALREX?
- What is Average Wholesale Price for ALREX?
Summary for ALREX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 63 |
| Patent Applications: | 4,390 |
| Drug Prices: | Drug price information for ALREX |
| Drug Sales Revenues: | Drug sales revenues for ALREX |
| What excipients (inactive ingredients) are in ALREX? | ALREX excipients list |
| DailyMed Link: | ALREX at DailyMed |
Pharmacology for ALREX
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for ALREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALREX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALREX
See the table below for patents covering ALREX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 302181 | ⤷ Sign Up | |
| Spain | 514633 | ⤷ Sign Up | |
| Norway | 812344 | ⤷ Sign Up | |
| Canada | 2174550 | SUSPENSION D'ETABONATE DE LOTEPREDNOL (SUSPENSION OF LOTEPREDNOL ETABONATE) | ⤷ Sign Up |
| Japan | 3570720 | ⤷ Sign Up | |
| Switzerland | 648856 | SOFT-STEROIDE MIT ANTI-INFLAMMATORISCHER AKTIVITAET. | ⤷ Sign Up |
| Italy | 1205446 | STEREOIDI METABOLIZZABILI O DEGRADABILI CAPACI DI ESPLICARE UN'AZIONE ANTIFLOGISTICA | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
